
Boris Hügle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7729440/publications.pdf Version: 2024-02-01



RODIS HÃ1/CLE

#	Article	IF	CITATIONS
1	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Annals of the Rheumatic Diseases, 2017, 76, 942-947.	0.9	175
2	Mutations in topoisomerase IIβ result in a B cell immunodeficiency. Nature Communications, 2019, 10, 3644.	12.8	37
3	Development of positive antinuclear antibodies and rheumatoid factor in systemic juvenile idiopathic arthritis points toward an autoimmune phenotype later in the disease course. Pediatric Rheumatology, 2014, 12, 28.	2.1	34
4	Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis. Pediatric Rheumatology, 2017, 15, 16.	2.1	30
5	Successful use of secukinumab in a 4-year-old patient with deficiency of interleukin-36 antagonist. Rheumatology, 2018, 57, 936-938.	1.9	30
6	Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study. Clinical and Experimental Rheumatology, 2016, 34, 148-54.	0.8	22
7	Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Longâ€Term Safety Data from the German <scp>BIKER</scp> Registry. ACR Open Rheumatology, 2020, 2, 37-47.	2.1	19
8	Education and employment in patients with juvenile idiopathic arthritis – a standardized comparison to the German general population. Pediatric Rheumatology, 2017, 15, 45.	2.1	17
9	Mutations in the MTHFR gene are not associated with Methotrexate intolerance in patients with juvenile idiopathic arthritis. Pediatric Rheumatology, 2016, 14, 11.	2.1	15
10	Infection with SARS-CoV-2 causes flares in patients with juvenile idiopathic arthritis in remission or inactive disease on medication. Pediatric Rheumatology, 2021, 19, 163.	2.1	14
11	Transcription factor motif enrichment in whole transcriptome analysis identifies STAT4 and BCL6 as the most prominent binding motif in systemic juvenile idiopathic arthritis. Arthritis Research and Therapy, 2018, 20, 98.	3.5	12
12	Impact of <i>IL1RN</i> Variants on Response to Interleukinâ€1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2020, 72, 499-505.	5.6	11
13	The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis. Expert Opinion on Pharmacotherapy, 2016, 17, 703-714.	1.8	10
14	Successful treatment of methotrexate intolerance in juvenile idiopathic arthritis using eye movement desensitization and reprocessing – treatment protocol and preliminary results. Pediatric Rheumatology, 2018, 16, 11.	2.1	8
15	Countermeasures against methotrexate intolerance in juvenile idiopathic arthritis instituted by parents show no effect. Rheumatology, 2017, 56, kew507.	1.9	7
16	Incidence of malignancies in patients with juvenile idiopathic arthritis: A retrospective single-center cohort study in Germany. Modern Rheumatology, 2017, 27, 60-65.	1.8	7
17	MTX intolerance in children and adolescents with juvenile idiopathic arthritis. Rheumatology, 2020, 59, 1482-1488.	1.9	7
18	Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis – data from the German AID-registry. Pediatric Rheumatology, 2021, 19, 38.	2.1	7

Boris Hügle

#	Article	IF	CITATIONS
19	Association between drug intake and incidence of malignancies in patients with Juvenile Idiopathic Arthritis: a nested case–control study. Pediatric Rheumatology, 2016, 14, 6.	2.1	3
20	The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 211-218.	3.0	2
21	Antinuclear Antibody-Positive Juvenile Idiopathic Arthritis Despite IRAK-4 Deficiency. Journal of Clinical Immunology, 2018, 38, 450-453.	3.8	2
22	In pediatric rheumatologic disease, methotrexate leads to mildly changed bloodwork on the second day after administration. Pediatric Rheumatology, 2022, 20, 23.	2.1	0